Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59112

Imesch, P; Samartzis, E P; Schneider, M; Fink, D; Fedier, A (2011). Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertility and Sterility, 95(5):1579-1583.

[img]Published Version
PDF - Registered users only
View at publisher


Objective: To investigate whether the histone deacetylase (HDAC) inhibitor romidepsin down-regulates VEGF (vascular endothelial growth factor) gene expression and abrogates VEGF protein secretion in human epithelial endometriotic cells. Design: In vitro study with human immortalized epithelial endometriotic cells. Setting: University hospital. Patient(s): Not applicable. Intervention(s): None.
Main Outcome Measure(s): Real-time reverse-transcriptase polymerase chain reaction to evaluate VEGF gene expression, immunoblot analysis to evaluate protein expression, and enzyme-linked immunosorbent assay to evaluate VEGF protein secretion into the culture medium. Result(s): Treatment of 11z human endometriotic cells with romidepsin statistically significantly inhibited VEGF gene transcription and down-regulated VEGF protein expression. Moreover, romidepsin abrogated the secretion of VEGF protein into the culture medium. Romidepsin also reduced the expression of hypoxia-inducible factor-1a (HIF-1a), which is implicated in the transcription of the VEGF gene, in cobalt chloride-pretreated (to mimic hypoxic conditions) 11z cultures.
Conclusion(s): Romidepsin targets VEGF at the transcriptional level, which subsequently leads to the reduction of secreted VEGF (the ‘‘active’’ form of VEGF). Therefore, romidepsin may be a potential therapeutic candidate against angiogenesis in endometriosis.


11 citations in Web of Science®
16 citations in Scopus®
Google Scholar™



2 downloads since deposited on 17 Feb 2012
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:610 Medicine & health
Deposited On:17 Feb 2012 10:18
Last Modified:05 Apr 2016 15:37
ISSN:0015-0282 (P) 1556-5653 (E)
Publisher DOI:10.1016/j.fertnstert.2010.12.058
PubMed ID:21295294

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page